# US 2023/0410977 A1 · Methods and materials for assessing radiation exposure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0410977 A1
- Document ID: US20230410977A1
- Status: Published application
- Kind: A1
- Application number: 18/268,721
- Filed: 2021-12-22
- Published: 2023-12-21
- Earliest claimed: 2020-12-22
- Applicants: NUtech Ventures
- Inventors: Alexandra Crook; Aline De Lima Leite; Thomas Payne; Fatema Bhinderwala; Robert Powers
- Web page: https://patentgrep.com/patent/US20230410977A1

## CPC

- G01N 33/5088: {of vertebrates}
- G01N 33/5091: {for testing the pathological state of an organism}
- A61N 5/103: {Treatment planning systems}
- G01N 33/5038: {involving detection of metabolites per se}
- G01N 33/57585: {involving compounds identifiable in body fluids}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 20/40: relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
- G01N 2800/40: Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
- G01N 2800/7066: Metabolic pathways
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

This document relates to methods and materials for assessing radiation exposure. For example, methods and materials that can be used to determine whether a mammal (e.g., a human) has been exposed to radiation and/or whether a mammal (e.g., a human) is at risk of developing one or more radiation injuries (e.g., cutaneous radiation injury (CRI) and/or acute radiation syndrome (ARS)) following radiation exposure (e.g., radiation therapy) are provided.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A method for treating a mammal having cancer, wherein said method comprises:
(a) detecting an absence of an altered level of at least five metabolites in a sample from said mammal; and
(b) administering a radiation therapy to said mammal.

### Claim 15 (depends on 14)

The method of claim 14, wherein said altered level of said at least five metabolites is an increased level, and wherein said at least five metabolites are selected from the group consisting of 10,11-dihydro-12r-hydroxy-leukotriene E4, 12-oxo-20-trihydroxy-leukotriene B4, 2-amino-3-phosphonopropionic acid, 3-hydroxybutyrate, 5-hydroxyindoleacetic acid, 5-hydroxytryptophol glucuronide, 7-methylguanosine, acetyldigitoxin, alpha-CEHC, D-glucose, formamidopyrimidine nucleoside triphosphate, gamma glutamylglutamic acid, gamma-glutamylthreonine, ganglioside GA1 (d18:1/16:0), ganglioside GM2 (d18:1/18:1(11z)), L-beta-aspartyl-L-threonine, leucyl-valine, leukotriene F4, L-isoleucine, L-leucine, lysoPC(22:2(13z,16z)), N-a-acetyl-L-arginine, N-acetyltryptophan, N-gamma-L-glutamyl-D-alanine, PG(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)), phenylalanylphenylalanine, phosphoribosyl-AMP, p-hydroxyphenylacetic acid, PS(14:0/14:l(9Z)), PS(20:4(5Z,8Z,11Z,14Z)/14:1(9Z)), pyruvate, tetrahexosylceramide (d18:1/16:0), trans-3-hydroxycotinine glucuronide, trimethylamine N-oxide, uridine, valine, vanylglycol, L-carnitine, tiglyl-CoA, 2,2-dimethylsuccinic acid, 3-methyl-2-oxovalerate, anserine, L-phenylalanine, L-tryptophan, N,N-Dimethylglycine, N6-acetyllysine, N-acetylysteine, propylene glycol, undecanoic acid, and xanthurenate.

### Claim 16 (depends on 14)

The method of claim 14, wherein said altered level of said at least five metabolites is a decreased level, and wherein said at least five metabolites are selected from the group consisting of 1-methylhistidine, 2-aminomuconic acid semialdehyde, 2-methylguanosine, 2-oxoarginine, 2-pyrroloylglycine, 3-(3,5-diiodo-4-hydroxyphenyl)pyruvate, 3-dehydroxycarnitine, 3-hydroxyoctanoyl carnitine, 3-nitrotyrosine, 3′-O-methyladenosine, 4-guanidinobutanoic acid, 7-methylguanine, alanyl-serine, allantoic acid, argininic acid, arginyl-methionine, citric acid, creatine, cysteic acid, cysteinyl-cysteine, DL-2-aminooctanoic acid, dUMP, gamma-glutamyltyrosine, glutaminyl-lysine, glutarylcarnitine, glycerophosphocholine, glyceryl lactopalmitate, hippuric acid, IDP, L-acetylcarnitine, L-alanine, L-aspartyl-4-phosphate, L-carnitine, L-glutamine, L-histidine, L-isoleucine, L-phenylalanine, L-tyrosine, melatonin, N1-methyl-2-pyridone-5-carboxamide, N6,N6,N6-trimethyl-L-lysine, N-acetyl-L-methionine, nicotine imine, N-ribosylhistidine, 0-isobutyryl-L-carnitine, phenol sulphate, phenylpyruvic acid, picolinoylglycine, proline betaine, pyrogallol-2-O-glucuronide, riboflavin, serinyl-hydroxyproline, sphinganine 1-phosphate, trans-3-coumarate, tyrosyl-glutamate, urocanic acid, 1H-indole-3-carboxaldehyde, 2-hydroxyadenine, allodesmosine, arginyl-histidine, guanine, hypoxanthine, LysoPC(14:0), LysoPC(15:0), LysoPC(18:3(6Z,9Z,12Z)), LysoPE(0:0/18:1(11Z)), phosphoric acid, pyrrolidine, uridine, 1,9-dimethylurate, 2-(3-carboxy-3-aminopropyl)-L-histidine, adenosine diphosphate ribose, adenosine thiamine triphosphate, ADP, ATP, cholesterol glucuronide, D-galactose, D-glucose, GTP, malonyl-carnitin, N-acetyl-D-glucosamine, NAD+, NADH, NADP+, N-decanoylglycine, phosphoribosyl-AMP, purine, and tiglylcarnitine.

### Claim 17 (depends on 14)

The method of claim 14, wherein said detecting comprises LC-MS, NMR, GC-MS, CE-MS, FTIR, or combinations thereof.

### Claim 18

A method for treating a mammal having cancer, wherein said method comprises:
(a) detecting an absence of at least one enriched metabolic pathway in a sample from said mammal; and
(b) administering a radiation therapy to said mammal.

### Claim 19 (depends on 18)

The method of claim 18, wherein said at least one enriched metabolic pathway is selected from the group consisting of Warburg effect, arginine and proline metabolism, glutamate metabolism, pyruvate metabolism, fatty acid metabolism, propanoate metabolism, nicotinate and nicotinamide metabolism, gluconeogenesis, ammonia recycling, pyrimidine metabolism, urea cycle, selenoamino acid metabolism, mitochondrial beta-oxidation of long chain saturated fatty acids, mitochondrial beta-oxidation of short chain saturated fatty acids, cysteine metabolism, oxidation of branched chain fatty acids, glycolysis, purine metabolism, carnitine synthesis, glutathione metabolism, lactose synthesis, beta oxidation of very long chain fatty acids, and valine, leucine and isoleucine degradation.

### Claim 20 (depends on 14)

The method of claim 14, wherein said mammal is a human.

### Claim 21 (depends on 14)

The method of claim 14, wherein said sample is selected from the group consisting of whole blood, serum, plasma, urine, CSF, saliva, jejunum tissue, lung tissue, heart tissue, kidney tissue, skin tissue, bone marrow, gastrointestinal tract tissue, cardiovascular system tissue, CNS tissue, hematopoietic cells, and a fecal sample.

### Claim 22

A method for treating a mammal having cancer, wherein said method comprises:
(a) detecting a presence of an altered level of at least five metabolites in a sample from said mammal; and
(b) administering a cancer treatment to said mammal, wherein said cancer treatment is not a radiation therapy.

### Claim 23 (depends on 22)

The method of claim 22, wherein said altered level of said at least five metabolites is an increased level, and wherein said at least five metabolites are selected from the group consisting of 10,11-dihydro-12r-hydroxy-leukotriene E4, 12-oxo-20-trihydroxy-leukotriene B4, 2-amino-3-phosphonopropionic acid, 3-hydroxybutyrate, 5-hydroxyindoleacetic acid, 5-hydroxytryptophol glucuronide, 7-methylguanosine, acetyldigitoxin, alpha-CEHC, D-glucose, formamidopyrimidine nucleoside triphosphate, gamma glutamylglutamic acid, gamma-glutamylthreonine, ganglioside GA1 (d18:1/16:0), ganglioside GM2 (d18:1/18:1(11z)), L-beta-aspartyl-L-threonine, leucyl-valine, leukotriene F4, L-isoleucine, L-leucine, lysoPC(22:2(13z,16z)), N-a-acetyl-L-arginine, N-acetyltryptophan, N-gamma-L-glutamyl-D-alanine, PG(18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)), phenylalanylphenylalanine, phosphoribosyl-AMP, p-hydroxyphenylacetic acid, PS(14:0/14:1(9Z)), PS(20:4(5Z,8Z,11Z,14Z)/14:1(9Z)), pyruvate, tetrahexosylceramide (d18:1/16:0), trans-3-hydroxycotinine glucuronide, trimethylamine N-oxide, uridine, valine, vanylglycol, L-carnitine, tiglyl-CoA, 2,2-dimethylsuccinic acid, 3-methyl-2-oxovalerate, anserine, L-phenylalanine, L-tryptophan, N,N-Dimethylglycine, N6-acetyllysine, N-acetylysteine, propylene glycol, undecanoic acid, and xanthurenate.

### Claim 24 (depends on 22)

The method of claim 22, wherein said altered level of said at least five metabolites is a decreased level, and wherein said at least five metabolites are selected from the group consisting of 1-methylhistidine, 2-aminomuconic acid semialdehyde, 2-methylguanosine, 2-oxoarginine, 2-pyrroloylglycine, 3-(3,5-diiodo-4-hydroxyphenyl)pyruvate, 3-dehydroxycarnitine, 3-hydroxyoctanoyl carnitine, 3-nitrotyrosine, 3′-O-methyladenosine, 4-guanidinobutanoic acid, 7-methylguanine, alanyl-serine, allantoic acid, argininic acid, arginyl-methionine, citric acid, creatine, cysteic acid, cysteinyl-cysteine, DL-2-aminooctanoic acid, dUMP, gamma-glutamyltyrosine, glutaminyl-lysine, glutarylcarnitine, glycerophosphocholine, glyceryl lactopalmitate, hippuric acid, IDP, L-acetylcarnitine, L-alanine, L-aspartyl-4-phosphate, L-carnitine, L-glutamine, L-histidine, L-isoleucine, L-phenylalanine, L-tyrosine, melatonin, N1-methyl-2-pyridone-5-carboxamide, N6,N6,N6-trimethyl-L-lysine, N-acetyl-L-methionine, nicotine imine, N-ribosylhistidine, 0-isobutyryl-L-carnitine, phenol sulphate, phenylpyruvic acid, picolinoylglycine, proline betaine, pyrogallol-2-O-glucuronide, riboflavin, serinyl-hydroxyproline, sphinganine 1-phosphate, trans-3-coumarate, tyrosyl-glutamate, urocanic acid, 1H-indole-3-carboxaldehyde, 2-hydroxyadenine, allodesmosine, arginyl-histidine, guanine, hypoxanthine, LysoPC(14:0), LysoPC(15:0), LysoPC(18:3(6Z,9Z,12Z)), LysoPE(0:0/18:1(11Z)), phosphoric acid, pyrrolidine, uridine, 1,9-dimethylurate, 2-(3-carboxy-3-aminopropyl)-L-histidine, adenosine diphosphate ribose, adenosine thiamine triphosphate, ADP, ATP, cholesterol glucuronide, D-galactose, D-glucose, GTP, malonyl-carnitin, N-acetyl-D-glucosamine, NAD+, NADH, NADP+, N-decanoylglycine, phosphoribosyl-AMP, purine, and tiglylcarnitine.

### Claim 25 (depends on 22)

The method of claim 22, wherein said detecting comprises LC-MS, NMR, GC-MS, CE-MS, FTIR, or combinations thereof.

### Claim 26

A method for treating a mammal having cancer, wherein said method comprises:
(a) detecting a presence of at least one enriched metabolic pathway in a sample from said mammal; and
(b) administering a cancer treatment to said mammal, wherein said cancer treatment is not a radiation therapy.

### Claim 27 (depends on 26)

The method of claim 26, wherein said at least one enriched metabolic pathway is selected from the group consisting of Warburg effect, arginine and proline metabolism, glutamate metabolism, pyruvate metabolism, fatty acid metabolism, propanoate metabolism, nicotinate and nicotinamide metabolism, gluconeogenesis, ammonia recycling, pyrimidine metabolism, urea cycle, selenoamino acid metabolism, mitochondrial beta-oxidation of long chain saturated fatty acids, mitochondrial beta-oxidation of short chain saturated fatty acids, cysteine metabolism, oxidation of branched chain fatty acids, glycolysis, purine metabolism, carnitine synthesis, glutathione metabolism, lactose synthesis, beta oxidation of very long chain fatty acids, and valine, leucine and isoleucine degradation.

### Claim 28 (depends on 22)

The method of claim 22, wherein said mammal is a human.

### Claim 29 (depends on 22)

The method of claim 22, wherein said sample is selected from the group consisting of whole blood, serum, plasma, urine, CSF, saliva, jejunum tissue, lung tissue, heart tissue, kidney tissue, skin tissue, bone marrow, gastrointestinal tract tissue, cardiovascular system tissue, CNS tissue, hematopoietic cells, and a fecal sample.

### Claim 30 (depends on 22)

The method of claim 22, wherein said cancer treatment comprises administering an anti-cancer agent selected from the group consisting of a chemotherapeutic agent, a targeted cancer drug, an immunotherapy drug, and a hormone therapy drug.

### Claim 31 (depends on 22)

The method of claim 22, wherein said cancer treatment comprises surgery.

### Claim at position 20

32-45. (canceled)

### Claim 46 (depends on 18)

The method of claim 18, wherein said mammal is a human.

### Claim 47 (depends on 18)

The method of claim 18, wherein said sample is selected from the group consisting of whole blood, serum, plasma, urine, CSF, saliva, jejunum tissue, lung tissue, heart tissue, kidney tissue, skin tissue, bone marrow, gastrointestinal tract tissue, cardiovascular system tissue, CNS tissue, hematopoietic cells, and a fecal sample.

### Claim 48 (depends on 26)

The method of claim 26, wherein said mammal is a human.

### Claim 49 (depends on 26)

The method of claim 26, wherein said sample is selected from the group consisting of whole blood, serum, plasma, urine, CSF, saliva, jejunum tissue, lung tissue, heart tissue, kidney tissue, skin tissue, bone marrow, gastrointestinal tract tissue, cardiovascular system tissue, CNS tissue, hematopoietic cells, and a fecal sample.

### Claim 50 (depends on 26)

The method of claim 26, wherein said cancer treatment comprises administering an anti-cancer agent selected from the group consisting of a chemotherapeutic agent, a targeted cancer drug, an immunotherapy drug, and a hormone therapy drug.

### Claim 51 (depends on 26)

The method of claim 26, wherein said cancer treatment comprises surgery.
